Collectively, we found that IL-22 gene therapy could exert favorable effects on established DN via simultaneously alleviating systemic metabolic syndrome and downregulating renal NLRP3 inflammasome activation (Supplementary Figure 7). This evidence concerns the gene NLRP3 and liver dysplastic nodule.